Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma

Dasatinib (DAS) is a potent inhibitor of the BCR-ABL, SRC, c-KIT, PDGFR, and ephrin tyrosine kinases that has demonstrated only modest clinical efficacy in melanoma patients. Given reports suggesting that DAS enhances T cell infiltration into the tumor microenvironment, we analyzed whether therapy e...

Descripción completa

Detalles Bibliográficos
Autores principales: Lowe, Devin B, Bose, Anamika, Taylor, Jennifer L, Tawbi, Hussein, Lin, Yan, Kirkwood, John M, Storkus, Walter J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984268/
https://www.ncbi.nlm.nih.gov/pubmed/24734217
http://dx.doi.org/10.4161/onci.27589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984268/
https://www.ncbi.nlm.nih.gov/pubmed/24734217
http://dx.doi.org/10.4161/onci.27589

Ejemplares similares